- Home
- CCBG vs PCRX Comparison
CCBG vs PCRX Comparison
Compare CCBG & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCBG | PCRX |
|---|---|---|
| Founded | 1895 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 726.2M | 1.0B |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | CCBG | PCRX |
|---|---|---|
| Price | $42.62 | $26.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $45.00 | $32.86 |
| AVG Volume (30 Days) | 62.1K | ★ 870.0K |
| Earning Date | 01-27-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.43% | N/A |
| EPS Growth | ★ 17.47 | N/A |
| EPS | ★ 3.57 | 0.47 |
| Revenue | $246,433,000.00 | ★ $716,791,000.00 |
| Revenue This Year | $12.46 | $6.24 |
| Revenue Next Year | $3.24 | $9.53 |
| P/E Ratio | ★ $12.00 | $55.18 |
| Revenue Growth | ★ 9.03 | 3.14 |
| 52 Week Low | $32.38 | $18.17 |
| 52 Week High | $45.63 | $27.64 |
Technical Indicators
Market Signals| Indicator | CCBG | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.54 | 63.49 |
| Support Level | $42.54 | $25.56 |
| Resistance Level | $45.48 | $27.16 |
| Average True Range (ATR) | 0.99 | 1.03 |
| MACD | -0.23 | 0.01 |
| Stochastic Oscillator | 28.61 | 80.73 |
Price Performance
Historical ComparisonAbout CCBG Capital City Bank Group
Capital City Bank Group Inc is a United States-based group engaged in Banking services, Trust and asset management services, and Brokerage services. The company operates in one segment with two principal services: Banking Services and Wealth Management Services. It offers retail and commercial banking business in the form of traditional deposit and credit services, asset management, trust, mortgage banking, merchant services, bank cards, data processing, and securities brokerage services among others through its banking offices in Florida, Georgia, and Alabama.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.